Post by PharmaShots

AstraZeneca reports the P-III (I CAN) trial results on Ultomiris in IgA Nephropathy, delivering rapid and significant proteinuria reduction, supporting its potential as a disease-modifying C5 complement inhibitor Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #astrazeneca #ultomiris #igan #clinicaltrial #ican #ravulizumab #upcr #era2026 https://lnkd.in/gBye4UZb